Market Research Report

Nuclear Cardiology Markets
cover Published by Trimark Publications
Published Product code 203893
Content info 252 Pages
Price

Introduction

Abstract

image1

Report Discription

Nuclear imaging for cardiac diseases helps in accurately diagnosing the disease and blood flow blockages. Gamma cameras and positron emission tomography (PET) scanners are the key imaging devices used for cardiac procedures. Though nuclear imaging in cardiology faces competition from other methods, the impact is relatively limited. Demand for diagnostic medical imaging equipment is mainly driven by the number of diagnostic procedures. The application of PET' s clinical use, its combined use with other imaging equipment and the current shift to PET/CT imaging and SPECT/CT imaging are the important factors driving the dramatic rise in procedural volumes. This TriMark Publications study discusses key products in nuclear cardiology and examines the trends that are stimulating this market. This market research report includes a survey of all major companies actively engaged in marketing, manufacturing or developing nuclear cardiological instrumentation, with each company discussed in depth. The primarily focus on three major segments of the nuclear cardiology market: 1) devices, 2) PACS (picture archiving and communications systems) and RIS (radiology information systems) and 3) radiopharmaceuticals. This examination discusses products, trends, new developments and compensation issues that are currently affecting or are likely to affect the nuclear cardiology market soon. Detailed tables and charts with sales forecasts and market share data are also included.

Table of Contents

Table of Contents

1. Overview 14

  • 1.2 Scope
  • 1.3 Methodology
  • 1.4 Executive Summary

2. Overview of Cardiovascular Diseases (CVD)

  • 2.1 Heart Diseases in Men
  • 2.2 Heart Diseases in Women
  • 2.3 Prevalence of Cardiovascular Diseases in the U.S.
    • 2.3.1 Prevalence of CVD in Ethnic Groups: U.S.
    • 2.3.2 Global CVD Mortality
    • 2.3.3 Economic Cost of CVD in the U.S.
    • 2.3.4 CVD Mortality in Europe
  • 2.4 CVD Mortality in China
  • 2.5 CVD Prevalence and Mortality in India
  • 2.6 Aneurysm
    • 2.6.1 Detection of Aneurysm
  • 2.7 Angina
    • 2.7.1 Prevalence of Angina
  • 2.8 Atherosclerosis
    • 2.8.1 Imaging of Atherosclerosis
  • 2.9 Cerebrovascular Accident (Stroke)
    • 2.9.1 Embolic Stroke
    • 2.9.2 Cerebral Hemorrhage
    • 2.9.3 Subarachnoid Hemorrhage
    • 2.9.4 Imaging Devices Used for Detecting Stroke
  • 2.10 Congestive Heart Failure
    • 2.10.1 Imaging Modalities Used for the Detection of Congestive Heart Failure
  • 2.11 Coronary Artery Disease (CAD)
    • 2.11.1 Imaging of CAD
  • 2.12 Nuclear Imaging for Heart Diseases
    • 2.12.1 Technological Advances in Nuclear Cardiology
      • 2.12.1.1 Development of New Pharmacologic Stress Agents and Protocols
      • 2.12.1.2 Development of New Tracers
      • 2.12.1.3 New Computer Algorithms and Tools
      • 2.12.1.3 New Gamma Camera Technology
      • 2.12.1.4 Hybrid Systems and Image Fusion
  • 2.13 Trends in Cardiac Imaging

3. Popular Modalities Used in Nuclear Cardiology

  • 3.1 SPECT/CT
    • 3.1.1 General Architecture of SPECT/CT
    • 3.1.2 Myocardial Perfusion Imaging: CT Based Attenuation Correction
    • 3.1.4 SPECT/CT for Cardiac Disease Detection: An Economic Conundrum
    • 3.1.4.1 SPECT/CT from the Physician' s Point of View
    • 3.1.4.2 Cost Effectiveness vs. Cost and Reimbursement
    • 3.1.4.3 Factors to Drive Sales and Utilization of SPECT/CT
    • 3.1.4.4 Newer SPECT Cameras
    • 3.1.4.5 New Ultrafast Camera Designs
    • 3.1.4.6 Basic Design of a Gamma Camera
  • 3.2 Positron Emission Tomography (PET)
    • 3.2.1 Basic Design of a PET System
    • 3.2.2 Application of PET in Cardiology
    • 3.2.3 PET and Heart Disease Diagnosis
    • 3.2.4 PET and Heart Disease Staging
    • 3.2.5 Reimbursement Cuts for Cardiac PET in 2011
    • 3.2.6 Growth of PET in Cardiology
      • 3.2.6.1 PET/CT Hybridization
      • 3.2.6.2 Cost Considerations in PET Scanners
    • 3.2.7 PET/CT in Cardiology
    • 3.2.7.1 Positron Emitting Tracers
    • 3.3.1 The Resting Electrocardiogram (ECG)
    • 3.3.2 The Exercise Stress Test (Treadmill Stress Test, TMT)
    • 3.3.3 Echocardiography
    • 3.3.4 Magnetic Resonance Imaging (MRI)
    • 3.3.5 Multi-slice Computed Tomography (MSCT)
    • 3.3.6 Contrast Coronary Angiography (CA) and Intravascular Ultrasound (IVUS)

4. Nuclear Medicine

  • 4.1 Diagnostic Radiopharmaceuticals
  • 4.2 Suppliers of Radioisotopes
  • 4.3 Isotopes Used in Medicine
  • 4.4 Cyclotron Radioisotopes
  • 4.5 Radiopharmaceuticals in PET Imaging
  • 4.6 Radiopharmaceuticals for Clinical Cardiac PET Imaging
    • 4.6.1 Nitrogen-13 Ammonia
    • 4.6.2 Rubidium-82
    • 4.6.3 Oxygen-15 Water
    • 4.6.4 Fluorine-18 Fluorodeoxyglucose
  • 4.7 Generator Produced PET Radiopharmaceuticals
  • 4.8 Radiopharmaceuticals in SPECT

5. Picture Archiving and Communication Systems (PACS) in Cardiology

  • 5.1 Trends in Cardiology PACS
    • 5.1.1 Remote Reading of PACS
    • 5.1.2 Double-Digit Growth in CardioPACS

6. Advances in Nuclear Cardiology

  • 6.1 Myocardial Function
  • 6.2 Myocardial Perfusion
  • 6.3 Gated Myocardial Perfusion SPECT
  • 6.4 Advances in Software for Gated SPECT
  • 6.5 Gated Myocardial Perfusion SPECT in the Era of Multi-Detector CT
  • 6.6 PET and Imaging of Myocardial Metabolism
  • 6.7 Imaging Myocardial Innervation
  • 6.8 Radionuclide Imaging of Atherosclerotic Lesions
  • 6.9 Stem Cell Imaging
  • 6.10 Gene Therapy

7. Current Status of Nuclear Cardiology

  • 7.1 Current Status of Nuclear Cardiology in Asia
  • 7.2 Current Status of Nuclear Cardiology in Europe
    • 7.2.1 European Cardiovascular Disease Statistics
  • 7.3 Current Status of Nuclear Cardiology in Latin America
  • 7.4 Current Status of Nuclear Cardiology in North America

8. Nuclear Cardiology: Market Analysis

  • 8.1 Global Utilization of Nuclear Cardiology
    • 8.1.1 Future of Global Nuclear Cardiology Utilization
    • 8.1.2 Utilization of Nuclear Cardiology Procedures in Developed Countries
    • 8.1.3 Utilization of Nuclear Cardiology Procedures in Latin America
    • 8.1.4 Utilization of Nuclear Cardiology Procedures in Asia/Oceania
    • 8.1.5 Utilization of Nuclear Cardiology in Africa
  • 8.2 Utilization of Nuclear Cardiology vs. Mortality Rate
  • 8.3 Cost Effectiveness in Nuclear Cardiology
  • 8.4 Epidemiology of Cardiovascular Diseases in Developing Countries
  • 8.5 Global Opportunities for Nuclear Cardiology Products
  • 8.6 Global Market for SPECT/PET
  • 8.7 SPECT/PET Technology
  • 8.8 Competition in Nuclear Cardiology Market
  • 8.9 Global Market for SPECT
  • 8.10 Product Comparisons of Gamma Cameras
    • 8.10.1 Mobile Gamma Cameras
    • 8.10.2 SPECT Cameras
    • 8.10.3 Purchase Considerations for SPECT Cameras
    • 8.10.4 Cost Containment
  • 8.11 Need for Dedicated PET Devices for Cardiac Imaging
  • 8.12 Market for PET Imaging Systems
    • 8.12.1 Growth Rate for PET Cameras
    • 8.12.2 The Decline of SPECT
    • 8.12.3 PET-Only vs. PET/CT
    • 8.12.4 The Different Paths of SPECT/CT and PET/CT
  • 8.13 U.S. Market for PET
  • 8.14 PET Market in Europe
    • 8.14.1 European Market for Nuclear Imaging Equipment
    • 8.14.2 Nuclear Imaging Market Leaders in Europe
    • 8.14.3 European Market for PET/CT
    • 8.14.4 European Market for SPECT/CT
    • 8.14.5 Nuclear Imaging System Market in Germany
    • 8.14.6 Nuclear Imaging System Market in France
    • 8.14.7 Nuclear Imaging System Market in the U.K.
    • 8.14.8 Nuclear Imaging System Market in Italy
  • 8.15 PET Services in Europe
    • 8.15.1 PET Services in England
  • 8.16 SPECT vs. PET in Nuclear Cardiology
    • 8.16.1 Future of SPECT and PET
  • 8.17 Hybrid Economics
    • 8.17.1 Hybrid Optimization
    • 8.17.2 Image Quality
    • 8.17.3 Rapid Growth of Radio Tracers
  • 8.18 U.S. Market for SPECT and PET Radiopharmaceuticals
  • 8.19 U.S. Reimbursement for Nuclear Cardiology Procedures
  • 8.20 FDG Utilization in Europe
  • 8.21 Future of Radiopharmaceutical Tracers
  • 8.22 Global Market for Mo-99/Tc-99m
    • 8.22.1 Global Demand for Mo-99 by Geography
  • 8.23 Impact of Technetium Shortage on Cardiology Procedures
    • 8.23.1 Global Impact
    • 8.23.2 Popular Uses of Technetium-99M
  • 8.24 FDA-Approved Radiopharmaceuticals
  • 8.25 Cardiology Picture Archiving and Communication Systems (Cardiology PACS)
    • 8.25.1 Growth of Cardiology PACS
    • 8.25.2 Global Market for Cardiology PACS
    • 8.25.3 U.S. Market for Cardiology PACS
  • 8.26 General Medical Picture Archiving and Communication Systems (PACS)
    • 8.26.1 PACS Adoption
    • 8.26.2 Global Market for PACS
  • 8.27 PACS Installations in U.S. Hospitals
    • 8.27.1 PACS Modality Installations
    • 8.27.2 PACS Vendor Market Share
    • 8.27.3 PACS Image Distribution
  • 8.28 European Market for PACS
  • 8.29 PACS in India
    • 8.29.1 Market Insight
  • 8.30 Healthcare IT
    • 8.30.1 Hospital Information System (HIS)
    • 8.30.2 Electronic Medical Records (EMR)
    • 8.30.3 U.S. HIS Market
    • 8.30.4 U.S. Healthcare IT Industry

9. Company Profiles

  • 9.1 3mensio Medical Imaging BV
    • 9.1.1 3mensio Vascular
    • 9.1.3 3mensio SDK
    • 9.1.4 3mensio Valves
  • 9.2 AccuSync Medical Research Corporation
    • 9.2.1 AccuSync 42
    • 9.2.2 SpectroAnalyser
  • 9.3 Astellas Pharma US, Inc.
    • 9.3.1 Adenoscan (Adenosine)
    • 9.3.2 Lexiscan
  • 9.4 Bracco Diagnostics, Inc.
    • 9.4.1 CardioGen-82
  • 9.5 Capintec, Inc.
    • 9.5.1 CapIMAGE SFOV Gamma Camera
  • 9.6 Cardinal Health, Inc.
    • 9.6.1 Cardinal' s Cardiology Solutions
      • 9.6.1.1 LABStart
      • 9.6.1.2 LABComplete
      • 9.6.1.3 LABManage
      • 9.6.1.4 CardioWriter
  • 9.7 Covidien, PLC
    • 9.7.1 Covidien' s Nuclear Medicine Products
      • 9.7.1.1 Duosafe
      • 9.7.1.2 Indium In 111 Chloride Sterile Solution
      • 9.7.1.3 Octreoscan
      • 9.7.1.4 Sodium Iodide I 131 Capsules
      • 9.7.1.5 Technescan HDP
      • 9.7.1.6 Thallous Chloride TI 201
      • 9.7.1.7 The Ultra-Technekow Dry-Top Eluting (DTE)
      • 9.7.1.8 Gallium Citrate Ga 67 Injection
      • 9.7.1.9 Tc 99m Sestamibi
      • 9.7.1.10 Sodium iodide I-123
      • 9.7.1.11 Technescan MAG3
      • 9.7.1.12 Technescan PYP
    • 9.7.1.13 Ultratag RBC
  • 9.8 Digirad Corporation
    • 9.8.1 Cardius 2M XPO
    • 9.8.2 Cardius 3 XPO
    • 9.8.3 Cardius x.act
  • 9.9 FluoroPharma, Inc.
    • 9.9.1 FluoroPharma' s Technology
      • 9.9.1.1 CardioPET
      • 9.9.1.2 BFPET
      • 9.9.1.3 VasoPET
  • 9.10 Fujifilm Medical Systems USA, Inc.
    • 9.10.1 Fujifilm' s Cardiology Products
      • 9.10.1.1 Synapse Cardiovascular
      • 9.10.1.2 Corridor4DM
  • 9.11 GE Healthcare
    • 9.11.1 CardIQ Function Xpress
    • 9.11.2 CardIQ Fusion
    • 9.11.3 ReportCard 4
    • 9.11.4 CardIQ Physio
    • 9.11.5 Innova EPVision
    • 9.11.6 SmartScore 4.0
    • 9.11.7 Dynamic VUE
    • 9.11.8 Flow Analysis 4
    • 9.11.9 Left Ventricle Analysis
    • 9.11.10 StarMap 4
    • 9.11.11 Stenosis Analysis
    • 9.11.12 BrightSpeed Elite 16 slice
    • 9.11.13 BrightSpeed Edge Select 8 Slices
    • 9.11.14 HiSpeed CT/e (Single Slice)
    • 9.11.15 LightSpeed Xtra
    • 9.11.17 Ambulatory ECG-Holter
    • 9.11.18 MAC Resting ECG
    • 9.11.19 Discovery MR750
    • 9.11.20 Discovery MR450
  • 9.12 GVI Medical Devices
    • 9.12.1 ClearVision
    • 9.12.2 mSPECT
    • 9.12.3 OnePass
  • 9.13 Hermes Medical Solutions, Inc.
    • 9.13.1 Hermes' Cardiology Products
      • 9.13.1.1 QBS - Blood Pool Gated SPECT Analysis
      • 9.13.1.2 Hermes Hybrid Recon 163
      • 9.13.1.3 FBP - Filtered Backprojection SPECT Reconstruction
      • 9.13.1.4 FUGA - Gated Heart Analysis
      • 9.13.1.5 HOSEM - Iterative Reconstruction
      • 9.13.1.6 PERFIT - Cardiac Perfusion Analysis
      • 9.13.1.7 QGS - Gated SPECT Ejection Fraction Analysis
      • 9.13.1.8 QPS - Quantitative Perfusion SPECT
      • 9.13.1.9 Quick Cardiac
      • 9.13.1.10 Static Study Display
      • 9.13.1.11 Volume Display
  • 9.14 Lantheus Medical Imaging, Inc.
    • 9.14.1 Ablavar 167
    • 9.14.2 Definity (Perflutren Lipid Microsphere)
    • 9.14.3 Cardiolite
    • 9.14.4 Vialmix
  • 9.15 Medisco Imaging
    • 9.15.1 Spirit DH-V
    • 9.15.2 Cardio-C 169
    • 9.15.3 CardioSPECT D90
    • 9.15.4 Nucline AP
    • 9.15.5 X-Ring/R
    • 9.15.6 X-Ring/4R
    • 9.15.7 Nucline TH
  • 9.16 MIM Software, Inc.
    • 9.16.1 MIMfusion
    • 9.16.2 MIMcardiac
    • 9.16.3 MIMviewer
    • 9.16.4 MIM Storage Server
  • 9.17 Neusoft Medical Systems Co., Ltd.
    • 9.17.1 Truesight PET
    • 9.17.2 BeyondImage Workstation
    • 9.17.3 CardioCARE
    • 9.17.4 PETCare
  • 9.18 Numa, Inc.
    • 9.18.1 NumaLink
    • 9.18.2 NumaList
    • 9.18.3 NumaList Plus
    • 9.18.5 NumaRead
    • 9.18.6 NumaServer
    • 9.18.7 NumaManage
    • 9.18.8 Numa' s Core Lab System
  • 9.19 Thinking Systems Corporation
    • 9.19.1 MDStation 179
    • 9.19.2 MDStation for PET and PET/CT
  • 9.20 UltraSPECT, Ltd.
    • 9.20.l Xpress.Cardiac
    • 9.20.1 Xpress3.Cardiac
  • 9.21 Merge Healthcare, Inc.
    • 9.21.1 Merge ECM
    • 9.21.2 Fusion PACS Archive
    • 9.21.3 Merge Cardio
    • 9.21.4 Merge Hemo
    • 9.21.5 AMICAS PACS
    • 9.21.6 Fusion Workstation
    • 9.21.2 Fusion PACS GL
  • 9.22 Pharmalucence, Inc.
    • 9.22.1 Sestamibi
    • 9.22.2 Mebrofenin
    • 9.22.3 Pyrophosphate Injection
    • 9.22.4 Pentetate Injection
    • 9.22.3 Hepatolite
    • 9.22.4 Medronate
    • 9.22.5 Sulfur Colloid
  • 9.23 Philips Healthcare
  • 9.24 Positron Corporation
    • 9.24.1 Attrius
    • 9.24.2 Cardio-Assist
    • 9.24.3 Radiopharmaceuticals
    • 9.24.4 Tech-Assist
  • 9.25 Segami Corporation
    • 9.25.1 Segami' s Workstations
      • 9.25.1.1 Oasis
      • 9.25.1.2 Mirage
      • 9.25.1.3 Acquisition
    • 9.25.2 Segami' s Viewing Stations
      • 9.25.2.1 DGSCOPE
      • 9.25.2.2 VebVue
  • 9.26 Siemens Healthcare
    • 9.26.1 Siemens' Cardiology Products
      • 9.26.1.1 Artis zeego
      • 9.26.1.2 AXIOM Artis U
      • 9.26.1.3 Artis zee
    • 9.26.2 Siemens' Molecular Imaging Products
      • 9.26.2.1 Biograph TruePoint PET/CT
      • 9.26.2.2 syngo.via
      • 9.26.2.3 Symbia T
      • 9.26.2.4 Symbia T16
      • 9.26.2.5 Symbia S
      • 9.26.2.6 Symbia T2
      • 9.26.2.7 Symbia T6
      • 9.26.2.8 Symbia E
      • 9.26.2.9 c.cam 193
      • 9.26.2.10 Symbia.net
    • 9.26.3 Siemens' Cardiology Reading Solutions
      • 9.26.3.1 Syngo Cardiology Engines
      • 9.26.3.2 syngo Multimodality Workplace (MMWP)
      • 9.26.3.3 syngo MI Workplace (MIWP)
  • 9.27 Shimadzu Corporation
    • 9.27.1 Shimadzu' s Angiography Systems
      • 9.27.1.1 BRANSIST safire HF9/HC9 Slender
      • 9.27.1.2 BRANSIST safire HB9 Slender
      • 9.27.1.3 BRANSIST safire VB9 Slender
      • 9.27.1.4 BRANSIST safire VF17
      • 9.27.1.5 BRANSIST safire VC17
      • 9.27.1.6 HeartSpeed 10F/10C
      • 9.27.1.7 CvisionPLUS
  • 9.28 Spacelabs Healthcare, Inc.
    • 9.28.1 Sentinel
  • 9.29 Spectrum Dynamics
    • 9.29.1 D SPECT
  • 9.30 Syntermed, Inc.
    • 9.30.1 Emory Cardiac Toolbox
    • 9.30.2 Syntermed Live
    • 9.30.3 Nuclear Report Professional (NRP)

APPENDIX

  • Appendix 1: ASNC Imaging Guidelines for Nuclear Cardiology Procedures
  • Appendix 1.1: PET and PET/CT Instrumentation
  • Appendix 1.2: PET Imaging-Crystal Types
  • Appendix 1.3: PET TOF Imaging
  • Appendix 1.4: PET/CT Imaging
  • Appendix 1.5: PET Imaging-Attenuation Correction
  • Appendix 1.6: PET QC Procedures
  • Appendix 1.7: CT QC Procedures
  • Appendix 1.8: Combined PET/CT QC Procedures
  • Appendix 1.9: Attenuation Correction
  • Appendix 1.10: Rb-82 Perfusion Imaging
  • Appendix 1.11: N-13 Ammonia Perfusion Imaging
  • Appendix 1.12: F-18 FDG Metabolism Imaging
  • Appendix 2: Supply of Radioisotopes for Medical Use
  • Appendix 2.1: Nuclear Medicine
  • Appendix 2.2: In Vivo Nuclear Medicine Procedures in Numbers
  • Appendix 2.3: Current In Vivo Nuclear Medicine Diagnostic Procedures
  • Appendix 2.4: Conventional Diagnostic Nuclear Medicine (Gamma/SPECT Imaging)
  • Appendix 2.4.1: Technetium-99M (Tc-99M)
  • Appendix 2.5: Recently Developed Diagnostic Methods: Positron Emission Tomography (PET)
  • Appendix 2.6: Impact of Radioisotope Shortages in Different Countries
  • Appendix 2.7: Current Supply Situation
  • Appendix 2.8: Research Reactors Producing Molybdenum-99
  • Appendix 2.9: Expected Use of Imaging Modalities in the Future
  • Appendix 3: The Medical Isotope Crisis
  • Appendix 3.1: Production and Separation Facilities
  • Appendix 3.2: The Crisis
  • Appendix 3.3: Status of Production Facilities in Operation
  • Appendix 3.4: New Projects
  • Appendix 4: Impact of CMS Changes and Healthcare Legislation on Nuclear Cardiology
  • Appendix 4.1: Reduction in Nuclear Cardiology Payments
  • Appendix 4.2: 2011 Physician Fee Schedule
  • Appendix 4.3: Hospital Reimbursement
  • Appendix 5: History and Development of PET
  • Appendix 5.1: Pioneering Ideas for PET
  • Appendix 5.2: The Development of PET
  • Appendix 5.3: PET' s Advancements and Performance in Research Sector
  • Appendix 5.4: PET' s Progression in the Clinical Sector
  • Appendix 5.5: PET' s Advancements of 1990s
  • Appendix 5.6: PET' s Ability to Identify Pathophysiology
  • Appendix 5.7: PET/CT Scanner in 2000s
  • Appendix 5.8: How PET Works
  • Appendix 5.8.1: Coincidence Detection
  • Appendix 5.8.2: Coincidence Imaging
  • Appendix 5.9: PET Scan Modes
  • Appendix 5.10: Obstacles to the Widespread Use of PET
  • Appendix 5.11: Dedicated PET Equipment
  • Appendix 6: Current State of the Art of PACS
  • Appendix 6.1: Components and Architecture of PACS
  • Appendix 6.2: Image Acquisition Component
  • Appendix 6.3: PACS Controller
  • Appendix 6.4: Database Server and Archiving System
  • Appendix 6.5: Short-Term Archive
  • Appendix 6.6: Long-Term Archive
  • Appendix 6.7: Workstations
  • Appendix 6.8: Network
  • Appendix 6.9: Communication Protocols
  • Appendix 6.9.1: DICOM Standard
  • Appendix 6.9.2: HL7 Standard
  • Appendix 6.10: Other Related Systems
  • Appendix 6.10.1: Hospital Information System (HIS)
  • Appendix 6.10.2: Radiology Information System (RIS)
  • Appendix 6.11: Current PACS Products and Software
  • Appendix 6.11.1: Agfa: IMPAX 6
  • Appendix 6.11.2: Siemens Syngo Suite
  • Appendix 6.11.3: OpenSourcePACS
  • Appendix 6.12: Future Trends and Developments in PACS
  • Appendix 7: Glossary of Terms
  • Appendix 8: Abbreviation Guide for Cardiovascular Terms
  • Appendix 9: Molybdenum-99 Production, 2010-2020
  • Appendix 9.1: The Challenges and the Needs for Radionuclides (2010-2020)
  • Appendix 9.2: Long Term: Structural Supply Shortage
  • Appendix 9.3: Radionuclides Demand for Medical Purposes
  • Appendix 9.3.1: Conventional Nuclear Medicine Procedures Using 99mTc/99Mo (1990-2020)
  • Appendix 9.3.2: Global Market for 99mTc/99Mo, 1990-2020
  • Appendix 9.3.3: Growth of 99Mo Requirements, 1990-2020

INDEX OF FIGURES

  • Figure 2.1: Cardiovascular Disease: The Single Largest Cause of Mortality in Adults
  • Figure 2.2: Prevalence of CVD in Four of the Ethnic Groups in the U.S.
  • Figure 2.3: Prevalence of Cardiovascular Diseases in Adults Age 20 and Older by Age and Sex
  • Figure 2.4: CVD Deaths vs. Cancer Deaths in the U.S.
  • Figure 2.5: Percentage Breakdown of Deaths from Cardiovascular Diseases
  • Figure 2.6: Costs of Major Cardiovascular Diseases in the U.S., 2010
  • Figure 2.7: Leading Causes of Death of European Men
  • Figure 2.8: Leading Causes of Death of European Women
  • Figure 2.9: Age-Adjusted Mortality Rates for Aortic Aneurysm per 100,000
  • Figure 2.10: Prevalence of Aneurysm by Age and Smoking History
  • Figure 2.11: Age-Adjusted Prevalence of Angina in Men and Women Aged 20 and Over in the U.S.
  • Figure 3.1: Cardiac PET HOPPS Payments in the U.S., 2008-2011
  • Figure 3.2: Sensitivity of MPS and Echocardiography Using Different Types of Stress
  • Figure 3.3: Specificity of MPS and Echocardiography Using Different Types of Stress
  • Figure 7.1: Increasing Number of Heart Failures in Europe, 2010-2020 72
  • Figure 7.2: CVD in Middle Income Countries
  • Figure 7.3: CVD in Developed Countries
  • Figure 8.1: Nuclear Cardiology Procedures per 100,000 of Population per Year for Developing vs. Developed Countries
  • Figure 8.2: Future of Nuclear Cardiology in 2014
  • Figure 8.3: Approximate Use of Cardiac Diagnostic Testing, U.S.
  • Figure 8.4: Utilization of Nuclear Cardiology in Developed Countries
  • Figure 8.5: Utilization of Nuclear Cardiology in Latin America
  • Figure 8.6: Utilization of Nuclear Cardiology in Asia/Oceania
  • Figure 8.7: Utilization of Nuclear Cardiology in Africa
  • Figure 8.8: Global Market for PET/SPECT, 2010-2016
  • Figure 8.9: Overall Global Installed Bases of PET/SPECT Systems, 2010-2016
  • Figure 8.10: Global SPECT Market, 2010-2017
  • Figure 8.11: Global Market for PET Scanners, 2010-2017
  • Figure 8.12: Projected Market Share of PET and SPECT in 2020
  • Figure 8.13: Growth Rate for PET and SPECT, 2011-2020
  • Figure 8.14: Number of Cameras: SPECT Switching to PET, 2011-2020
  • Figure 8.15: Estimated Cameras Installed-Base in Nuclear Cardiology, 2011-2020
  • Figure 8.16: U.S. Market for PET, 2009-2017
  • Figure 8.17: Location of PET Centers in Europe, 2010
  • Figure 8.18: Growth of Cyclotron Units in Europe, 2000-2010
  • Figure 8.19: European Market for Nuclear Imaging Equipment, 2010-2016
  • Figure 8.20: European Nuclear Imaging Market Share by Company, 2010
  • Figure 8.21: European Nuclear Imaging System Market for PET/CT, 2010-2017
  • Figure 8.22: European Market for SPECT/CT, 2010-2017
  • Figure 8.23: Nuclear Imaging Market in Germany, 2010-2017
  • Figure 8.24: Nuclear Imaging System Market in France, 2010-2017
  • Figure 8.25: Nuclear Imaging System Market in the U.K.
  • Figure 8.26: Nuclear Imaging System Market in Italy, 2010-20017
  • Figure 8.27: PET Studies per Million Populations in Europe
  • Figure 8.28: U.S. Market for SPECT and PET Radiopharmaceuticals, 2009-2017
  • Figure 8.29: Global Demand Trend for Mo-99/Tc-99m
  • Figure 8.30: Global Market for Mo-99 by Geography/Country, 2009
  • Figure 8.31: Composition of Nuclear Medical Procedures Where Technetium-99Mo Is Predominant
  • Figure 8.32: Approximate Global Demand for Molybdenum-99/Technetium-99
  • Figure 8.33: Cardiology PACS Market Share by Company, 2010
  • Figure 8.34: Global Cardiology PACS Market, 2010-2016
  • Figure 8.35: U.S. Cardiology PACS Market Share % by Vendors, 2010
  • Figure 8.36: Global Market for PACS, 2010-2016
  • Figure 8.37: Number of U.S. Hospitals with PACS Installed
  • Figure 8.38: Total Number of U.S. Hospitals vs. Hospitals with PACS Installed
  • Figure 8.39: PACS Replacement and New Purchases
  • Figure 8.40: PACS Modality Installations
  • Figure 8.41: PACS Vendor Market Share
  • Figure 8.42: PACS Image Distribution in Hospital Departments
  • Figure 8.43: PACS Images Accessibility by Physicians
  • Figure 8.44: RIS and PACS Interface
  • Figure 8.45: European PACS Market, 2010-2016
  • Figure 8.46: RIS/PACS Market in India
  • Figure 8.47: Total PACS Market in India
  • Figure 8.48: Leading Healthcare IT Solution: Global Vendors
  • Figure 8.49: Global Market for Hospital Information System, 2009-2016 133
  • Figure 8.50: Global Market for EMR, 2009-2016
  • Figure 8.51: U.S. Market for Hospital Information System (HIS), 2009-2016
  • Figure 8.52: North American Hospital IT Market ($2.7 Billion), 2010
  • Figure App. 2.1: Number of In Vivo Procedures Performed Globally 208
  • Figure App. 2.2: Impact of Supply Shortage in 34 European Countries, 2008
  • Figure App. 2.3: Estimation of the Relative Use of Modalities in 2008, 2015 and 2025
  • Figure App. 2.4: Estimation of the Use of Imaging Modalities in 2008, 2015 and 2025
  • Figure App. 2.5: Break-down of the Shares of SPECT Modalities
  • Figure App. 5.1: Schematic of Smart Scanner
  • Figure App. 5.2: CT Image, PET Image and Fused Image
  • Figure App. 5.3: Collision of a Positron and Electron and the Two Resultant Gamma Rays
  • Figure App. 5.4: Discharge of Two Gamma Rays at 1800
  • Figure App. 5.5: Coincidence Detection
  • Figure App. 5.6: A Sinogram with Coincidence Lines
  • Figure App. 9.1: Global Number of Nuclear Medicine Procedures Using 99mTc/99Mo, 1990-2020
  • Figure App. 9.2: Weekly Quantities of 99Mo Delivered to End-Users Worldwide, 1990-2020
  • Figure App. 9.3: Quantity of 99Mo Delivered to End-Users by Geography, 2007
  • Figure App. 9.4: Regional Shares of Reactor Production of 99Mo, 2007
  • Figure App. 9.5: Regional Shares of Reactor Production & Requirements of 99Mo, 2007
  • Figure App. 9.6: Regional shares of reactor production & requirements of 99Mo, 2008

INDEX OF TABLES

  • Table 2.1: Males and Cardiovascular Diseases in the U.S.
  • Table 2.2: Females and Cardiovascular Diseases in the U.S.
  • Table 2.3: Ethnic Groups and Cardiovascular Diseases in the U.S.
  • Table 2.4: Forecasting the Prevalence Rate (%) of Coronary Heart Disease (CHD) in India, 2000-2015
  • Table 2.5: Forecasting of Cases of Stroke in India
  • Table 3.1: Characteristics of SPECT vs. PET
  • Table 3.2: Characteristics of Positron Emitting Tracers Used in PET Perfusion Imaging
  • Table 8.1: PET scanning Facilities in England
  • Table 8.2: PET scanning Facilities in Europe
  • Table 8.3: Medicare Physician Fee Schedule for Nuclear Cardiology Procedures
  • Table 8.4: Reimbursement for Cardiac CT Procedures
  • Table 8.5: Reimbursement for Stress Tests
  • Table 8.6: Radiopharmaceuticals in Clinical Use in European Countries
  • Table 8.7: Useful Radionuclides for Molecular Imaging
  • Table 8.8: Worldwide Production Capacity of 99Mo, 2009
  • Table 8.9: Small-Scale Producers of 99Mo, 2010
  • Table 8.10: Nuclear Medicine Procedures that Use 99mTc
  • Table 8.11: FDA-Approved Radiopharmaceuticals as of August 3, 2010
  • Table 9.1: The Complete List of Medical Imaging Products from GE Healthcare
  • Table 9.2: Philips' Computed Tomography Systems
  • Table 9.3: Philips' Nuclear Medicine Products
  • Table 9.4: Philips' Radiography Systems
  • Table 9.5: Philips' Radiography/Fluoroscopy Products
  • Table 9.6: Philips' Magnetic Resonance Imaging Products
  • Table App. 1.1: Suggested QC procedures for Dedicated PET Imaging Devices
  • Table App. 1.2: CT QC Procedures
  • Table App. 1.3: Schedule of CT QC for PET/CT Units
  • Table App. 1.4: Schedule of CT QC for PET/CT units
  • Table App. 1.5: General Guidelines for CT-Based Transmission Imaging
  • Table App. 1.6: Rb-82 Rest/Stress Myocardial Perfusion Imaging Guideline for BGO PET Imaging Systems
  • Table App. 1.7: Rb-82 Rest/Stress Myocardial Perfusion Imaging Guideline for GSO PET Imaging Systems
  • Table App. 1.8: N-13 Ammonia Cardiac Perfusion Studies
  • Table App. 1.9: FDG cardiac PET: Patient Preparation Guidelines: An Overview
  • Table App. 1.10: Guidelines for Blood Glucose Maintenance
  • Table App. 1.11: FDG Cardiac PET: Acquisition Guidelines for Dedicated, Multicrystal PET Scanner
  • Table App. 1.12: Semiquantitative Scoring System of Defect Severity and Extent
  • Table App. 2.1: Research Reactors Producing Radioisotopes
  • Table App. 3.1: Global Reactor Landscape
  • Table App. 3.2: Global Share of Nuclear Medicine by Reactor, 2009
  • Table App. 4.1: New CPT Codes and Global Payments for SPECT MPI Procedures, 2010
  • Table App. 4.2: CPT Code Changes and Payments for SPECT MPI Hospital-Based Procedures, 2010
  • Table App. 9.1: Radionuclides for Which Supply Is Believed to be in Jeopardy in 2010-2020

Nuclear Cardiology Markets published by Trimark Publications in May 1, 2011. This report consists of 252 Pages and the price starts from US $ 3400.

The contents of this page may be different from the latest version. Please contact us for details.
Back to Top